SLGL Stock Overview
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel.
No risks detected for SLGL from our risk checks.
Notes are coming soon
Sol-Gel Technologies Ltd. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$5.17|
|52 Week High||US$8.08|
|52 Week Low||US$3.94|
|1 Month Change||20.79%|
|3 Month Change||8.61%|
|1 Year Change||-30.97%|
|3 Year Change||-52.48%|
|5 Year Change||-51.23%|
|Change since IPO||-62.10%|
Recent News & Updates
Sol-Gel Technologies GAAP EPS of $0.01 beats by $0.11, revenue of $3.5M misses by $1.11MAug 04
These Analysts Think Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Sales Are Under ThreatMay 17
We Think That There Are Issues Underlying Sol-Gel Technologies' (NASDAQ:SLGL) EarningsApr 15
Downgrade: Here's How Analysts See Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Performing In The Near TermApr 05
We Think Sol-Gel Technologies (NASDAQ:SLGL) Can Afford To Drive Business GrowthNov 23
We Think Sol-Gel Technologies (NASDAQ:SLGL) Needs To Drive Business Growth CarefullyAug 04
Here's Why Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) CEO May Deserve A RaiseJul 01
Sol-Gel says no FDA notification regarding its marketing application for EPSOLAYApr 27
Newsflash: Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Analysts Have Been Trimming Their Revenue ForecastsMar 05
We're Not Very Worried About Sol-Gel Technologies' (NASDAQ:SLGL) Cash Burn RateFeb 02
What Type Of Returns Would Sol-Gel Technologies'(NASDAQ:SLGL) Shareholders Have Earned If They Purchased Their SharesYear Ago?Dec 29
FDA accepts Sol-Gel application for TwyneoDec 07
Sol-Gel: Slow And Steady Topical TechnologyNov 19
These Analysts Think Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Sales Are Under ThreatNov 18
Sol-Gel Technologies EPS beats by $0.09, beats on revenueNov 12
|SLGL||US Pharmaceuticals||US Market|
Return vs Industry: SLGL underperformed the US Pharmaceuticals industry which returned 4.6% over the past year.
Return vs Market: SLGL underperformed the US Market which returned -9.6% over the past year.
|SLGL Average Weekly Movement||7.5%|
|Pharmaceuticals Industry Average Movement||11.5%|
|Market Average Movement||6.7%|
|10% most volatile stocks in US Market||17.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: SLGL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: SLGL's weekly volatility (8%) has been stable over the past year.
About the Company
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company’s lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products.
Sol-Gel Technologies Ltd. Fundamentals Summary
|SLGL fundamental statistics|
Is SLGL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SLGL income statement (TTM)|
|Cost of Revenue||US$13.46m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.21|
|Net Profit Margin||19.90%|
How did SLGL perform over the long term?See historical performance and comparison